Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS
Acumen Pharmaceuticals stock price today
$1.4
-0.38
-21.35%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 2 hours
Acumen Pharmaceuticals stock price monthly change
-36.88%
month
Acumen Pharmaceuticals stock price quarterly change
-36.88%
quarter
Acumen Pharmaceuticals stock price yearly change
-53.65%
year
Acumen Pharmaceuticals key metrics
Market Cap | 105.74M |
Enterprise value | 23.07M |
P/E | -4.05 |
EV/Sales | N/A |
EV/EBITDA | -0.55 |
Price/Sales | N/A |
Price/Book | 0.81 |
PEG ratio | -0.05 |
EPS | -1.05 |
Revenue | N/A |
EBITDA | -65.68M |
Income | -55.93M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAcumen Pharmaceuticals stock price history
Acumen Pharmaceuticals stock forecast
Acumen Pharmaceuticals financial statements
| Jun 2023 | 0 | -11.61M | |
|---|---|---|---|
| Sep 2023 | 0 | -12.95M | |
| Dec 2023 | 290K | -16.49M | -5688.62% |
| Mar 2024 | 0 | -14.87M |
| Sep 2025 | 0 | -29.71M | |
|---|---|---|---|
| Oct 2025 | 0 | -25.47M | |
| Dec 2025 | 0 | -27.04M | |
| Dec 2025 | 0 | -26.74M |
Analysts Price target
Financials & Ratios estimates
| 2023-03-27 | -0.28 | -0.32 |
|---|---|---|
| 2023-05-09 | -0.33 | -0.28 |
| 2023-08-08 | -0.36 | -0.28 |
| 2023-11-13 | -0.31 | -0.24 |
| Jun 2023 | 177405000 | 8.53M | 4.81% |
|---|---|---|---|
| Sep 2023 | 286371000 | 6.09M | 2.13% |
| Dec 2023 | 310125000 | 43.15M | 13.91% |
| Mar 2024 | 300967000 | 38.93M | 12.94% |
| Jun 2023 | -11.67M | 11.06M | -145K |
|---|---|---|---|
| Sep 2023 | -12.90M | -92.00M | 122.76M |
| Dec 2023 | -8.31M | -48.80M | 29.13M |
| Mar 2024 | -17.85M | -9.20M | 7.10M |
Acumen Pharmaceuticals alternative data
| Aug 2023 | 39 |
|---|---|
| Sep 2023 | 39 |
| Oct 2023 | 39 |
| Nov 2023 | 39 |
| Dec 2023 | 39 |
| Jan 2024 | 39 |
| Feb 2024 | 39 |
| Mar 2024 | 39 |
| Apr 2024 | 39 |
| May 2024 | 51 |
| Jun 2024 | 51 |
| Jul 2024 | 51 |
Acumen Pharmaceuticals other data
11.34%
-55.57%
of ABOS is owned by hedge funds
23
-36
4.60M
-22.49M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 5161290 | 0 |
| Aug 2023 | 0 | 41949 |
| Jan 2024 | 0 | 34332 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | OCONNELL DANIEL JOSEPH director, officer: President an.. | Common Stock | 15,200 | $3.47 | $52,759 | ||
Sale | MEISNER DEREK M officer: Chief Le.. | Common Stock | 8,933 | $3.48 | $31,051 | ||
Sale | ZUGA MATT officer: CFO & Chief Business O.. | Common Stock | 4,242 | $3.71 | $15,717 | ||
Sale | SIEMERS ERIC officer: Chief Me.. | Common Stock | 3,124 | $3.71 | $11,603 | ||
Sale | BARTON RUSSELL officer: Chief Operating Officer | Common Stock | 2,833 | $3.73 | $10,556 | ||
Option | IVES JEFFREY L. director | Common Stock | 39,149 | $0.72 | $28,187 | ||
Option | IVES JEFFREY L. director | Common Stock | 2,800 | $1.19 | $3,332 | ||
Sale | IVES JEFFREY L. director | Common Stock | 41,949 | $6.57 | $275,605 | ||
Option | IVES JEFFREY L. director | Stock Option (right to buy) | 41,949 | $0.96 | $40,061 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: | Common Stock | 5,161,290 | $7.75 | $39,999,998 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 11 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Daniel J. O'Connell M.B.A. (1970) Chief Executive Officer, Pres & Director | $336,000 |
| Dr. Eric Siemers M.D. (1955) Chief Medical Officer | $237,600 |
Mr. Russell Barton M.S. (1958) Chief Operating Officer | $223,680 |
Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data
Acumen: A First In Targeting, May Lead To Improvement For Early AD Patients
Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
Trading Ideas On The Upcoming CTAD 2022 Conference
Acumen: ACU193 Is A Promising Phase 1 Alzheimer's Candidate, But Not More Than That
-
What's the price of Acumen Pharmaceuticals stock today?
One share of Acumen Pharmaceuticals stock can currently be purchased for approximately $1.4.
-
When is Acumen Pharmaceuticals's next earnings date?
Unfortunately, Acumen Pharmaceuticals's (ABOS) next earnings date is currently unknown.
-
Does Acumen Pharmaceuticals pay dividends?
No, Acumen Pharmaceuticals does not pay dividends.
-
How much money does Acumen Pharmaceuticals make?
Acumen Pharmaceuticals has a market capitalization of 105.74M. Acumen Pharmaceuticals made a loss 52.37M US dollars in net income (profit) last year or -$0.24 on an earnings per share basis.
-
What is Acumen Pharmaceuticals's stock symbol?
Acumen Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ABOS".
-
What is Acumen Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Acumen Pharmaceuticals?
Shares of Acumen Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Acumen Pharmaceuticals's key executives?
Acumen Pharmaceuticals's management team includes the following people:
- Mr. Daniel J. O'Connell M.B.A. Chief Executive Officer, Pres & Director(age: 55, pay: $336,000)
- Dr. Eric Siemers M.D. Chief Medical Officer(age: 70, pay: $237,600)
- Mr. Russell Barton M.S. Chief Operating Officer(age: 67, pay: $223,680)
-
How many employees does Acumen Pharmaceuticals have?
As Jul 2024, Acumen Pharmaceuticals employs 51 workers, which is 31% more then previous quarter.
-
When Acumen Pharmaceuticals went public?
Acumen Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 1 Jul 2021.
-
What is Acumen Pharmaceuticals's official website?
The official website for Acumen Pharmaceuticals is acumenpharm.com.
-
Where are Acumen Pharmaceuticals's headquarters?
Acumen Pharmaceuticals is headquartered at 427 Park Street, Charlottesville, VA.
-
How can i contact Acumen Pharmaceuticals?
Acumen Pharmaceuticals's mailing address is 427 Park Street, Charlottesville, VA and company can be reached via phone at +43 4297 1000.
Acumen Pharmaceuticals company profile:
Acumen Pharmaceuticals, Inc.
acumenpharm.comExchange:
NASDAQ
Full time employees:
51
Industry:
Biotechnology
Sector:
Healthcare
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
427 Park Street
Charlottesville, VA 22902
Charlottesville, VA 22902
CIK: 0001576885
ISIN: US00509G2093
CUSIP: 00509G209
